间充质干细胞治疗衰弱的临床研究:治疗与机制探索的实验设计
该文提出一项在越南开展的随机对照I/II期临床试验设计,评估异体脐带来源间充质干细胞(UC-MSCs)联合标准治疗对衰弱老年人的安全性和潜在疗效。主要结局为给药相关不良事件和严重不良事件发生率,疗效通过衰弱状况、生活质量、免疫与代谢标志物等评估,并分析UC-MSCs质量与患者CD3+细胞衰老等机制。
要点
- UC-MSCs联合标准治疗用于衰弱老年人,主要观察给药相关不良事件与严重不良事件。
- 疗效评估涵盖衰弱状况、患者报告结局、生活质量、免疫与代谢及细胞因子标志物。
- 机制分析包括UC-MSCs质量、细胞因子/生长因子分泌谱及患者CD3+细胞衰老与代谢。
核心结论
- 该随机对照I/II期试验旨在评估异体UC-MSCs联合标准治疗对衰弱老年人的安全性和潜在疗效。
研究设计与样本
- 随机对照I/II期临床试验,在越南开展,干预为异体UC-MSCs联合衰弱标准治疗。
- 试验注册号为NCT04919135。
主要发现
- 原文未报告试验结果,仅描述研究设计与分析方法。
- 既往临床前和临床研究支持间充质干细胞治疗衰弱的安全性。
关键数值与推荐
- 主要结局指标为预设给药相关不良事件和严重不良事件的发生率。
- 潜在疗效基于衰弱状况改善评估,包括体格检查、患者报告结局、生活质量、衰弱免疫标志物、代谢分析及患者血浆细胞因子标志物。
临床怎么用
- 该设计为未来开展UC-MSCs治疗衰弱的研究提供方案参考,尚不能直接指导临床用药。
- 临床解读需关注给药相关不良事件和严重不良事件的监测。
局限性
- 原文为试验设计描述,未提供实际研究结果或疗效数据。
- 研究在越南开展,结论外推需考虑人群与医疗环境差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Frailty, a specific condition of increased vulnerability and reduced general health associated with aging in older people, is an emerging problem worldwide with major implications for clinical practice and public health. Recent preclinical and clinical studies have supported the safety of mesenchymal stem/stromal cells (MSCs) in the treatment of frailty. Comprehensive study is needed to assess the interrelationship between the condition of frailty and the effects of MSC-based therapy. This randomized controlled phase I/II trial aims to investigate the safety and potential therapeutic efficacy of the allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) in combination with the standard treatment for frailty in Vietnam. Moreover, this study describes the rationales, study designs, methodologies, and analytical strategies currently employed in stem cell research and clinical studies. The primary outcome measures will include the incidences of prespecified administration-associated adverse events and serious adverse events. The potential efficacy will be evaluated based on improvements in frailty conditions (including those determined through a physical examination, patient-reported outcomes, quality of life, immune markers of frailty, metabolism analysis, and cytokine markers from patient plasma). This clinical trial and stem cell analysis associated with patient sampling at different time points aim to identify and characterize the potential effects of UC-MSCs on improving frailty based on the stem cell quality, cytokine/growth factor secretion profiles of UC-MSCs, cellular senescence, and metabolic analysis of patient CD3+ cells providing fundamental knowledge for designing and implementing research strategies in future studies. Clinical Trials Registration Number: NCT04919135.
引用
- Hoang DM, Nguyen KT, Hoang VT, et al. Clinical Study of Mesenchymal Stem/Stromal Cell Therapy for the Treatment of Frailty: A Proposed Experimental Design for Therapeutic and Mechanistic Investigation. J Gerontol A Biol Sci Med Sci. 2022. PMID: 34718548. doi:10.1093/gerona/glab326
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。